Clinical Trials



When you participate in a clinical trial you help pave the way for new treatments

What is a clinical trial?
A clinical trial is a critical step in the process of getting a new treatment approved so that it can be given to patients. After a drug is thoroughly tested in a lab, a clinical trial is designed to test it and make sure that it is effective and safe, and has the desired effect on the condition it is intended to treat. Many drugs never get off the ground because there are not enough volunteers. Don’t let that happen with new pancreatitis treatments. You have the power to propel research and development toward a cure! Learn more about what is involved in these pancreatitis clinical trials to see if they are right for you.

WebMAP CP

Researchers at Seattle Children’s Hospital want to learn more about pain management strategies to help youth with chronic pancreatitis. The study might be a good fit for you if you/your child is between 10 and 17 years old and has chronic or acute recurring pancreatitis. Families who participate will answer questions about pain, mood, sleep, and everyday life at 3 times over 9 months and use a website for 8-12 weeks, which might help with managing pain. Families will receive $100 for each completed assessment ($300 in total). Results from this study may help other children who have chronic pain. To participate in this study or learn more, please contact the study team at 1-855-932-6272 or palermolab@seattlechildrens.org.

SHARP

Researchers at the Medical University of South Carolina are researching whether a procedure called Endoscopic Retrograde CholangioPancreatography (ERCP) with sphincterotomy reduces the risk of pancreatitis or the number of recurrent pancreatitis episodes in patients with pancreas divisum. ERCP with sphincterotomy is a procedure where doctors used a combination of x-rays and an endoscope (a long flexible lighted tube) to find the opening of the duct where fluid drains out of the pancreas. Adults 18 years and older who have been diagnosed with pancreas divisum, have had at least two episodes of pancreatitis within the last 24 months, and are candidates for the ERCP with sphincterotomy procedure may be eligible to participate. Participants will have follow up visits 30 days after the procedure, 6 months after the procedure, and continuing every 6 months until a maximum follow-up period of 48 months.  There are 16 sites for the trial. For more information, contact Dr. Gregory Cote at 843-792-6999 or cotea@musc.edu.

QST Study: Predicting Treatment Response in Chronic Pancreatitis Using Quantitative Sensory Testing

Quantitative Sensory Testing (QST) is a novel investigative technique used in other pain conditions to evaluate patterns of chronic pain, and in this study will be used to elucidate pain patterns in patients with Chronic Pancreatitis (CP). QST uses a specific series of standardized stimulations to map the pain system. QST has the potential to change and improve the treatment paradigm for patients with CP and may eventually be able to predict response to invasive CP therapies.

Pancreatic Quantitative Sensory Testing (P-QST) to Predict Treatment Response for Pain in Chronic Pancreatitis (P-QST)

Abdominal pain in chronic pancreatitis (CP) affects up to 90% of patients during the course of their disease, and response to currently available therapies is suboptimal and unpredictable. The proposed clinical trial will evaluate the predictive capability of Pancreatic Quantitative Sensory Testing (P-QST) – a novel assessment of neurosensory phenotyping- for improvement in pain in patients with CP who are undergoing medically-indicated invasive treatment with endoscopic therapy or surgery.

Interventional Study: Role of a CCK Receptor Antagonist Proglumide in Management of Chronic Pancreatitis (ProCP)

Researchers at Georgetown University & MedStar Washington Hospital Center are looking for subjects interested in participating in a clinical trial to test a new treatment for chronic pancreatitis. A receptor protein call the CCK-B receptor becomes activated in chronic pancreatitis and is in part responsible for the scar tissue or fibrosis that occurs and responsible for the cancer risk. In mice with chronic pancreatitis, the inflammation and damage was reversed with an old drug called proglumide that blocks the activation of the CCK-B receptor. Proglumide has also been shown to possibly reduce pain. This clinical trial aims to test the safety of a CCK receptor antagonist, Proglumide, in the management of chronic pancreatitis symptoms and pain for 12 to 24 months.